Follow this blog:
RSS

Rethinking cancer by knowing its DNA

By | December 17, 2009, 6:06 AM PST

The successful DNA sequencing of lung cancer, and the 23,000 mutations separating it from normal cells, is a milestone in cancer study if not treatment.

Improvements in treatment, like tagging cells and then zapping them with energy, are still all on the cellular level. A cancer cell is like a person and we must kill it to live.

The results of DNA sequencing in treatment will be different. They will not be brute force. They will give us a personalized view of the cancer killing us, and perhaps drugs that go after just the cancer we have. We may get new tests for pre-cancer.

What scientists in England and the U.S. have really uncovered is a giant puzzle. Which of these 23,000 lung cancer mutations, or the 30,000 in skin cancer, transform a cell into a monster? We don’t know.

It’s interesting to think that, based on the math, we cause a mutation in our lung’s DNA for each 15 cigarettes smoked, but what does that get us, really?

Once the cell turns to cancer, it’s kill it or be killed.

You can best think of the new discoveries as akin to finding the Rosetta Stone. Here we have a way of translating from the language of cancer to the language of a normal cell. We can expand on that knowledge and translate back-and-forth among all normal and abnormal DNA structures, with time and computing power.

But the why and the how are still out there, a whole undiscovered country scientists are only now able to explore. While we continue battling cancer with brute force.

Start your week smarter with our weekly e-mail newsletter. It's your cheat sheet for good ideas. Get it.

Dana Blankenhorn

About Dana Blankenhorn

Dana Blankenhorn was a contributing editor for SmartPlanet from 2009 to 2010.

Dana Blankenhorn

Dana Blankenhorn

Contributing Editor, Healthcare

Dana Blankenhorn has written for the Chicago Tribune, Advertising Age's "NetMarketing" supplement and founded the Interactive Age Daily for CMP Media. He holds degrees from Rice and Northwestern universities. He is based in Atlanta.

Follow him on Twitter.

Dana Blankenhorn

Dana Blankenhorn

Dana Blankenhorn has been a technology reporter since 1982, a business reporter since 1978, and a writer for as long as he can remember. His Schwab IRA has a few tech stocks in it, most notably some Intel and Applied Materials bought over 10 years ago. But the vast majority of his tiny fortune (emphasis on the word tiny) is invested in mutual funds. He presently writes for no one else but ZDNet, SmartPlanet and himself. But if you've got an opportunity let him know. If he takes the gig he"ll first add it to this disclosure page.

He writes for SmartPlanet and is not an employee of CBS.

If you liked this, don't miss...
The discussion hasn’t started yet. Why don’t you begin it?
Formatting +
BB Codes - Note: HTML is not supported in forums
  • [b] Bold [/b]
  • [i] Italic [/i]
  • [u] Underline [/u]
  • [s] Strikethrough [/s]
  • [q] "Quote" [/q]
  • [ol][*] 1. Ordered List [/ol]
  • [ul][*] · Unordered List [/ul]
  • [pre] Preformat [/pre]
  • [quote] "Blockquote" [/quote]

Join the SmartPlanet community and join the conversation! Signing up is fast and free. Don't wait -- we want to hear your opinion!